16-substituted-4-aza-androstane 5-alpha-reductase isozyme 1 inhibitors
CA 2173863 C · Owner: Merck & Co. Inc. · Inventors: Hagmann, William K.; Sahoo, Soumya P.; Von Langen, Derek
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Compounds of formula (I) are inhibitors of the 5.alpha.-reductase 1 isozyme, and are useful alone or in, combination with a 5.alpha.-reductase 2 inhibitor. for the treatment of androgenic sensitive disorders such as acne vulgaris, seborrhea, female hirsutism male pattern, baldness, and benign prostatic hyperplasia.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 21, 1994 and granted May 13, 2003. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended October 21, 2014.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 21, 2016.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.